← Product Code [LZG](/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/LZG) · K050971 # BIOVALVE INSULIN DELIVERY SYSTEMS (BIDS) (K050971) _Biovalve Technologies, Inc. · LZG · Aug 16, 2005 · General Hospital · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/LZG/K050971 ## Device Facts - **Applicant:** Biovalve Technologies, Inc. - **Product Code:** [LZG](/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/LZG.md) - **Decision Date:** Aug 16, 2005 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 880.5725 - **Device Class:** Class 2 - **Review Panel:** General Hospital - **Attributes:** Therapeutic ## Indications for Use The BioValve Insulin Delivery System (BIDS) is indicated for the continuous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. ## Device Story BioValve Insulin Delivery System (BIDS) is a disposable insulin infusion pump for basal and bolus insulin delivery. Unlike electronic predicate devices, BIDS is a non-electronic, non-software-controlled mechanical device. It provides continuous insulin delivery for diabetes management. It is intended for use by patients requiring insulin therapy. ## Clinical Evidence No clinical data provided; substantial equivalence supported by performance data. ## Technological Characteristics Disposable insulin infusion pump. Non-electronic; contains no electronic components or software. Mechanical delivery mechanism for basal and bolus insulin. ## Regulatory Identification An infusion pump is a device used in a health care facility to pump fluids into a patient in a controlled manner. The device may use a piston pump, a roller pump, or a peristaltic pump and may be powered electrically or mechanically. The device may also operate using a constant force to propel the fluid through a narrow tube which determines the flow rate. The device may include means to detect a fault condition, such as air in, or blockage of, the infusion line and to activate an alarm. ## Predicate Devices - Insulet iXL Diabetes Management System ([K031373](/device/K031373.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ ## 510(K) SUMMARY #### 9.0 Summary of Safety and Effectiveness | 9.1 Submitted By: | Scott Huie | |----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------| | | Vice President of Operations | | | Biovalve Technologies, Inc | | Date Prepared: | April 15, 2005 | | | 9.2 Trade/Proprietary Name: BioValve Insulin Delivery Systems (BIDS) | | 9.3 Common/Usual Name: | Disposable Insulin Infusion Pump | | 9.4 Classification Name: | Pump, Infusion, Insulin/Set, Administration, Intravascular | | 9.5 Classification: FDA has classified Infusion Pumps and Intravascular Catheters in
Class II. Final Order was published in the Federal Register on October 21, 1980 after
review by the General Hospital and Personal Use Devices Classification Panel. | | | Panel: 80 Procodes: | LZG External Insulin Infusion Pump
FPA Intravascular Administration Set | | 9.6 Purpose of Submission
BioValve Technologies proposes to market a disposable pump for the basal and bolus
delivery of insulin. | | ### 9.7 Substantial Equivalence The BioValve Insulin Delivery Systems (BIDS) is substantially equivalent to the Insulet iXL Diabetes Management System (K031373) as well as other Insulin Infusion Pumps and Subcutaneous Insulin Infusion Sets. #### 9.8 Technological Characteristics The technological characteristics for these devices differ from the predicate devices in as much as this device does not use electronic power or components nor is it software controlled. #### 9.9 Performance Data The information provided supports that the performance of the pumps is equivalent to the predicate devices. #### 9.10 Conclusion Biovalve, Inc. concludes based on the information presented that the modified product is substantially equivalent to the current product legally marketed in the USA. {1}------------------------------------------------ Image /page/1/Picture/1 description: The image shows the logo for the Department of Health and Human Services (HHS). The logo features a stylized depiction of an eagle or bird-like figure with three curved lines representing its wings or feathers. The bird is positioned within a circular border, and the text "DEPARTMENT OF HEALTH AND HUMAN SERVICES - USA" is arranged around the circumference of the circle. AUG 1 6 2005 Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Mr. Scott Huie Vice President of Operations BioValve Technologies, Incorporated 155 Flanders Rd. Westborough, Massachusetts 01581 Re: K050971 Trade/Device Name: BioValve Insulin Delivery Systems (BIDS) Regulation Number: 21 CFR 880.5725 Regulation Name: Insulin Infusion Pump Regulatory Class: II Product Code: LZG Dated: June 30, 2005 Received: July 1, 2005 Dear Mr. Huie: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {2}------------------------------------------------ Page 2 - Mr. Huie Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers. International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours, Chiu Lin, Ph.D. Director Director Division of Anesthesiology, General Hospital Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {3}------------------------------------------------ # Indications for Use 510(k) Number (if known): K050971 Device Name: BioValve Insulin Delivery Systems (BIDS) Indications For Use: The BioValve Insulin Delivery System (BIDS) is indicated for the continuous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. Prescription Use (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use _________________________________________________________________________________________________________________________________________________________ (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Chr (Division Sign-Off) Division of Anesthesiology, General Hospital, Infection Control, Dental Devices Page 1 of 510(k) Number: --- **Source:** [https://fda.innolitics.com/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/LZG/K050971](https://fda.innolitics.com/submissions/HO/subpart-f%E2%80%94general-hospital-and-personal-use-therapeutic-devices/LZG/K050971) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com